

Gilead Sciences, Inc.

08:24 24 Mar 2020

S&P/ASX 200 futures down 1.2% heading into the open, US markets fall overnight

S&P/ASX 200 (INDEXASX:XJO) (ASX:XJO) futures are down 1.2% heading into the open but have rebounded from their earlier lows with optimistic investors calling for a bounce today.

Overnight, the S&P 500 Index (INDEX:. INX) closed at 2,237.40, ?67.52 or down 2.93% and the Nasdaq Composite (INDEXNASDAQ: .IXIC) closed at 6,860.67, ?18.84 or down 0.27%.

With two red sessions in the US now on Friday and Monday, the market is due for good news.

US Congress is debating an economic stimulus bill, which when passed could provide the reprieve the market desperately needs short term.

Alternatively, the market may focus on the US FDA this morning granting potential COVID19 treatment drug Remdesivir with an Orphan Drug Designation.

Remdesivir is a novel antiviral drug developed by Gilead Sciences, Inc. (NASDAQ:GILD).

Gold and oil higher overnight

Gold was up 5.1% overnight to US\$1,560 per ounce and Crude Oil WTI was up 5.1% to US\$23.80 per barrel.

The AUD is buying 58.2 US cents which is largely unchanged at -0.2% overnight.


[REPORT] Wall St falls further as investors wait on a US stimulus package to pass the Senate <https://t.co/YwmhB4ZKJi> #ausbiz #markets pic.twitter.com/20M141Dgcv

— CommSec (@CommSec) March 23, 2020

Price: 76.35

Market Cap: \$95.78 billion

1 Year Share Price Graph



Share Information

Code: GILD

Listing: NASDAQ

52 week	High	Low
	85.97	60.9

Sector: Medical technology & services

Website: www.gilead.com

Company Synopsis:

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes therapeutics. The Company sells and distributes Truvada, Viread, Emtriva, Hepsera and AmBisome in Asia, Australia, Europe, Latin America, the Middle East and New Zealand, through its commercial teams, third party distributors or partners.

action@proactiveinvestors.com.au

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 action@proactiveinvestors.com.au

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.